

Pfizer Quality Improvement RFP

Improving Cancer Care in Patients with Metastatic Breast Cancer

Competitive Grant Program –Pfizer Internal Review Process



Overview

Pfizer is launching a competitive grant program seeking to support Quality Improvement projects to measurably improve the quality of care in patients with metastatic Breast Cancer (mBC). Patients with mBC face many challenges in obtaining optimal cancer care for various reasons. We encourage initiatives addressing disparities and challenges in underserved patient populations.



Geographic Scope

Kazakhstan



Project Types and Area of Interest

Projects that identify and address barriers to patients receiving optimal care, from pre-diagnosis through all phases of treatment and care for metastatic breast cancer.

We are particularly interested in proposals that focus on the following areas: improving diagnosis and access to novel medicines; patient navigation programs; multidisciplinary care team approaches; educational resources development and use; health literacy and digital skills acquisition for patients; improving doctor-patient relationships and communication; the use of technology to facilitate remote access medical care and access to second opinions from clinicians or diagnostic specialists (such as a phone or video consult).



Key Milestones

- Application submission deadline: August 28, 2023
- Anticipated decision notification date: October 2023
- Anticipated project start date: From December 2023 onwards



Funding Range and Project Length

- Projects requesting up to 5,000,000 KZT will be considered. The total available budget related to this RFP is 10,000,000 KZT.
- Project length should not exceed 24 months.

I. Eligibility

Geographic Scope:

- Kazakhstan

Applicant Eligibility Criteria

- Only organizations are eligible to receive grants, not individuals or medical practice groups.
- The following may apply: public healthcare bodies (city/ regional hospitals, oncology centers, multidisciplinary medical centers, oncology dispensaries and polyclinics), or accredited private hospitals that are involved in the care of oncology patients, research institutes, universities, professional associations, medical societies, NGOs, patients' organizations and other entities with a mission related to healthcare improvement.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. All institutions must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the Project Lead/Principal Investigator (PI) or an authorized designee of such individual (e.g., Project Lead/PI's grant/research coordinator).
- The Project Lead/PI must be an employee or independent contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer Kazakhstan. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer Kazakhstan may be subject to rescission.

II. Requirements

Date RFP Issued

- July 25, 2023

Clinical Area

- Oncology, Metastatic Breast Cancer

General Area of Interest for this RFP:

Projects that will be considered for Pfizer support will focus on:

- Improving the quality of cancer care and access to care in patients with mBC.
- Initiatives addressing disparities and challenges in obtaining optimal cancer care, in underserved patient populations.

We are particularly interested in proposals that focus on improving the following areas:

- Diagnosis and access to novel medicines.
- Patient navigation programs to overcome health care system barriers and facilitate timely access to quality medical and psychological care.
- Multidisciplinary care team approach for cancer patients.
- Health literacy and digital skills acquisition among patients for engagement in disease management and treatment decision-making. Improving doctor-patient relationships and communication.

- Use of technology to facilitate remote medical care between patients and healthcare professionals (e.g. remote patient monitoring and virtual care).
- Remote access to second opinions from clinicians or diagnostic specialists (such as a phone or video consult).

Proposals should state clear goals, measurable outcomes and utilize evidence-based strategies to improve the management and care of mBC patients.

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Target Audience

- Metastatic Breast Cancer patients and their caregivers.
- Healthcare professionals involved in treatment and management of mBC patients.

Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to 5000000 KZT will be considered. The estimated total available budget related to this RFP is 10000000 KZT.

Key Dates:

- RFP release date: 7/25/2023
- Grant Application due date: 8/28/2023
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: October 2023
- Grants will be distributed following a fully executed agreement and submission of Final Protocol, documentation of IRB/IEC approval, regulatory approval (if applicable), exemption or waiver.
- Anticipated Project Start and End Dates: From December 2023 onwards, for a period not exceeding 24 months

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled

- Please go to www.cybergrants.com/pfizer/QI and sign in. First-time users should click "Create your password". [Note: there are individual portals for each grant application type. Please be sure to use the URL above.]
- Click the "Start a New Quality Improvement Application" button.
- In the application:
 - For the question "Competitive Grant?" select **Yes**
 - Select the following Competitive Grant Program Name: **2023 ONC mBC KZ QI**
 - Select the following Primary Area of Interest: **Oncology - Breast**
- Requirements for submission:

Complete all required sections of the online application and upload your project proposal (see Appendix) in the Full Proposal Submission field.
- If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, AP Lee, at GMGEMEA@pfizer.com, with the subject line “**2023 ONC mBC KZ QI, July 25, 2023**”
- Please click [here](#) to view Frequently Asked Questions regarding the Competitive Grant Program.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

References

- Bibliography of relevant references.

About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the practice gaps as outlined in the specific RFP.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Appendix

Quality Improvement Project Full Proposal

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Full Proposal documents should be no longer than 12 pages in length (12-point font and 1-inch margins) excluding Organization Detail and References. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s).
- List the overall objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target population as well as the outcomes you expect to achieve as a result of conducting the project.

Assessment of Need for the Project

- Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area. Describe the source and method used to collect the data. Describe how the data was analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information.

Target Audience

- Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population

Project Design and Methods

- Describe the planned project and the way it addresses the established need.
- If your methods include educational activities, please describe succinctly the topic(s) and format of those activities

Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed.
- Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how you will determine if the practice gap was addressed for the target group. Describe how you expect to collect and analyze the data.
- Quantify the amount of change expected from this project in terms of your target audience.
- Describe how the project outcomes will be broadly disseminated.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- The budget amount requested must be in KZT.
- While estimating your budget please keep the following items in mind:
 - General organizational running costs such as insurances, heating, lighting, rent, building maintenance may be included. Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
 - The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
 - It should be noted that grants awarded through GMG cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.